Plus Therapeutics (NASDAQ:PSTV – Get Free Report) and TherapeuticsMD (NASDAQ:TXMD – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, risk, analyst recommendations, profitability, valuation and earnings.
Valuation and Earnings
This table compares Plus Therapeutics and TherapeuticsMD”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Plus Therapeutics | $5.21 million | 7.69 | -$22.39 million | ($2.30) | -2.54 |
| TherapeuticsMD | $3.02 million | 7.74 | -$570,000.00 | ($0.01) | -202.00 |
Profitability
This table compares Plus Therapeutics and TherapeuticsMD’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Plus Therapeutics | -230.24% | -296.20% | -78.93% |
| TherapeuticsMD | 5.34% | 0.32% | 0.23% |
Risk and Volatility
Plus Therapeutics has a beta of 1.4, suggesting that its share price is 40% more volatile than the S&P 500. Comparatively, TherapeuticsMD has a beta of 0.58, suggesting that its share price is 42% less volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of current ratings and recommmendations for Plus Therapeutics and TherapeuticsMD, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Plus Therapeutics | 1 | 2 | 4 | 0 | 2.43 |
| TherapeuticsMD | 1 | 0 | 0 | 0 | 1.00 |
Plus Therapeutics presently has a consensus target price of $58.00, indicating a potential upside of 893.15%. Given Plus Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Plus Therapeutics is more favorable than TherapeuticsMD.
Institutional & Insider Ownership
3.3% of Plus Therapeutics shares are owned by institutional investors. Comparatively, 30.7% of TherapeuticsMD shares are owned by institutional investors. 2.5% of Plus Therapeutics shares are owned by insiders. Comparatively, 1.7% of TherapeuticsMD shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
About Plus Therapeutics
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection. It has license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.
About TherapeuticsMD
TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.
Receive News & Ratings for Plus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Plus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
